Posted under Startups
from http://www.xconomy.com/ 873 days ago

Luke Timmerman

Genentech has spent more than a decade developing a souped-up version of its multi-billion dollar breast cancer drug, and today it is delivering hard evidence on cancer R&D’s biggest stage that it works.

The South San Francisco-based biotech company, a unit of Roche, has shown that its experimental drug trastuzumab emtansine (T-DM1) hit its main goal in a study of 991 patients with breast cancer that overexpresses the HER2 protein, and who have previously been treated with the original trastuzumab (Herceptin) and a taxane chemotherapy. The new drug, which combines the targeting capability of the original trastuzumab with a toxin to give it more tumor-killing punch, was able to keep cancer from spreading a median time of about 3.2 months longer than a combination of two other drugs. The new Genentech drug—which uses a chemical linker from Waltham, MA-based ImmunoGen—caused tumors to shrink ...

Read More...

blog comments powered by Disqus
Editor's Pick
Popular Today